Core Viewpoint - Novo Nordisk anticipates challenges in its international operations in 2026 due to increased competition following the loss of market exclusivity in several countries [1] Company Summary - CEO Mike Doustdar highlighted the expectation of headwinds for the company in 2026 [1]

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant. ...